These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2994982)

  • 1. History of the development of inhibitors of angiotensin I conversion.
    Ferreira SH
    Drugs; 1985; 30 Suppl 1():1-5. PubMed ID: 2994982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. University discoveries and intellectual property rights: from Bothrops jararaca bradykinin potentiating peptides to angiotensin converting enzyme inhibitors.
    Ferreira SH
    Braz J Med Biol Res; 1994 Aug; 27(8):1693-8. PubMed ID: 7749362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin processing activities in the venom of Thalassophryne nattereri.
    Tenório Hde A; Marques ME; Machado SS; Pereira HJ
    Toxicon; 2015 May; 98():49-53. PubMed ID: 25702959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From viper's venom to drug design: treating hypertension.
    Patlak M
    FASEB J; 2004 Mar; 18(3):421. PubMed ID: 15003987
    [No Abstract]   [Full Text] [Related]  

  • 7. The discovery of captopril: a reply.
    Smith CG; Vane JR
    FASEB J; 2004 Jun; 18(9):935. PubMed ID: 15173103
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel bradykinin potentiating peptide isolated from Bothrops jararacussu venom using catallytically inactive oligopeptidase EP24.15.
    Rioli V; Prezoto BC; Konno K; Melo RL; Klitzke CF; Ferro ES; Ferreira-Lopes M; Camargo AC; Portaro FC
    FEBS J; 2008 May; 275(10):2442-54. PubMed ID: 18400032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of captopril.
    Smith CG; Vane JR
    FASEB J; 2003 May; 17(8):788-9. PubMed ID: 12724335
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?
    Cruden NL; Newby DE
    Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History of heart failure.
    Ventura HO
    Congest Heart Fail; 2008; 14(6):329. PubMed ID: 19076858
    [No Abstract]   [Full Text] [Related]  

  • 12. [Biotransformation of prostaglandin E1, bradykinin and angiotensin I in pulmonary circulation in rats with spontaneous hypertension].
    Karpitskiĭ VV; Gomazkov OA
    Fiziol Zh (1978); 1985; 31(2):227-30. PubMed ID: 4039687
    [No Abstract]   [Full Text] [Related]  

  • 13. Bradykinin-potentiating peptides: beyond captopril.
    Camargo AC; Ianzer D; Guerreiro JR; Serrano SM
    Toxicon; 2012 Mar; 59(4):516-23. PubMed ID: 21835190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
    Hirsch S
    Compr Ther; 2009; 35(2):91-5. PubMed ID: 19618757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs inhibiting the renin - angiotensin system.
    Antonaccio MJ; Cushman DW
    Fed Proc; 1981 Jun; 40(8):2275-84. PubMed ID: 6263716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The renin-angiotensin system and its inhibition (author's transl)].
    Corvol P; Elkik F; Thibonnier M; Plouin PF; Menard J
    Nouv Presse Med; 1981 Apr; 10(19):1525-30. PubMed ID: 6269554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tribute to John H. Laragh, MD.
    Blumenfeld J
    Am J Hypertens; 2014 Aug; 27(8):1011-2. PubMed ID: 25103933
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of PGI2 and effects of ACE inhibition on the bradykinin potentiation by angiotensin-(1-7) in resistance vessels of SHR.
    Fernandes L; Fortes ZB; Casarini DE; Nigro D; Tostes RC; Santos RA; de Carvalho MH
    Regul Pept; 2005 Apr; 127(1-3):183-9. PubMed ID: 15680485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vaccine for hypertension.
    Ménard J
    J Hypertens; 2007 Jan; 25(1):41-6. PubMed ID: 17143170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.